 Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designation further increases Amniofixs chances of being approved, and gives MDXG the opportunity to apply for early approval after the Phase 2b knee OA trial is completed. 